Skip to main content

Checkmate Pharmaceuticals, Inc. (CMPI)

NASDAQ: CMPI · Delayed Price · USD
4.25
+0.03 (0.71%)
Pre-market:Oct 22, 2021 8:48 AM EDT
4.22
0.00 (0.00%)
At close: Oct 21, 12:00 AM
Market Cap89.53M
Revenue (ttm)n/a
Net Income (ttm)-55.44M
Shares Out21.62M
EPS (ttm)-2.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40
Open-
Previous Close4.22
Day's Range4.07 - 4.25
52-Week Range3.63 - 23.10
Betan/a
AnalystsBuy
Price Target18.33 (+334.4%)
Est. Earnings DateNov 11, 2021

About CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorp...

IndustryBiotechnology
IPO DateAug 7, 2020
Employees25
Stock ExchangeNASDAQ
Ticker SymbolCMPI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CMPI stock is "Buy." The 12-month stock price forecast is 18.33, which is an increase of 334.36% from the latest price.

Price Target
$18.33
(334.36% upside)
Analyst Consensus: Buy

News

Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)

Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET

1 day ago - GlobeNewsWire

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities. The Checkmate Pha...

2 weeks ago - Benzinga

Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technol...

1 month ago - GlobeNewsWire

Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing

2 months ago - GlobeNewsWire

Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

2 months ago - Business Wire

Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technolog...

5 months ago - GlobeNewsWire

Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technolo...

5 months ago - GlobeNewsWire

Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Com...

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technolo...

5 months ago - GlobeNewsWire

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-...

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technolo...

5 months ago - GlobeNewsWire

Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technol...

5 months ago - GlobeNewsWire

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technol...

6 months ago - GlobeNewsWire

Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Associ...

CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary techno...

6 months ago - GlobeNewsWire

7 Beaten Down Stocks with Significant Insider Buying

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

6 months ago - InvestorPlace

Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress

CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary techno...

6 months ago - GlobeNewsWire

Checkmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary techno...

7 months ago - GlobeNewsWire

Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

Robert F. Dolski appointed as Chief Financial Officer

9 months ago - GlobeNewsWire